Benzinga | Feb 25, 2021 04:01PM EST

Supernus Pharmaceuticals Q4 EPS $0.57 Beats $0.52 Estimate, Sales $143.56M Miss $146.19M Estimate

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.52 by 9.62 percent. This is a 8.06 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $143.56 million which missed the analyst consensus estimate of $146.19 million by 1.80 percent. This is a 42.92 percent increase over sales of $100.45 million the same period last year.